Publikationer – Peter Nygren

Publikationer i DiVA

Publikationer i PubMed

Ett urval av våra publikationer:

  1. Karlsson H, Fryknäs M, Senkowski W, Larsson R, Nygren P. Selective radiosensitization by nitazoxanide of quiescent clonogencic colon cancer tumour cells. Oncol Lett. 2022, 123, doi: 10.3892/ol.2022.13243.
  2. Ek F, Blom K, Selvin T, Rudfeldt J, Andersson C, Senkowski W, Brechot C, Nygren P, Larsson R, Jarvius M, Fryknäs M. Sorafenib and nitazoxanide disrupt mitochondrial function and inhibit regrowth capacity in three-dimensional models of hepatocellular and colorectal carcinoma. Sci Rep. 2022, l2, doi 10.1038/s41598-022-12519-4.
  3. Andersson C, Ye J, Blom K, Fryknäs M, Larsson R, Nygren P. Assessment in vitro of interactions between anti-cancer drugs and non-cancer drugs commonly used by cancer patients. Anticancer Drugs. 2022 doi: 10.1097/CAD.000000000001344.
  4. Bjersand K, Blom K, Poromaa IS, Stålberg K, Lejon AM, Bäckman F, Nyberg Å, Andersson C, Larsson R, Nygren P. Ex vivo assessment of cancer drug sensitivity in epithelial ovarian cancer and its association with histopathological type, treatment history and clinical outcome. Int J Oncol 128, 2022, doi: 10.3892/ijo.2022.5418.
  5. Mansoori S, Fryknäs M, Alvfors C, Loskog A, Larsson R, Nygren P. A phase 2a clinical study on the safety and efficacy of individualized dosed mebendazole in patients with advanced gastrointestinal cancer. Sci Rep 2021, 11:8981.
  6. Andersson CR, Selvin T, Blom K, Rubin J, Berglund M, Jarvius M, Lenhammar L, Parrow V, Loskog A, Fryknäs M, Nygren P, Larsson R. Mebendazole is unique among tubulin-active drugs in activating the MEK-ERK pathway: new treatment for diseases with defective ERK signaling. Scientific Rep. 2020, 10:13124.
  7. Rendo V, Stoimenov I, Mateus A, Sjöberg   E, Svensson  R, Gustavsson  A-L, Johansson  L, Ng  A, Obrien  C, Giannakis  M, Artursson  P, Nygren  P, Cheong I, Sjöblom  T. Exploiting loss of heterozygosity for allele-selective colorectal cancer chemotherapy. Nature Commun. 2020, 11:1308.
  8. Blom K, Rubin J, Berglund M, Jarvius M, Lenhammar L, Parrow V, Andersson C, Loskog A, Fryknäs M, Nygren P, Larsson R. Mebendazole-induced M1 polarization of THP-1 macrophages may involve DYRK1B inhibition. BMC Res Notes. 2019, 12: 234.
  9. Karlsson H, Senkowski W, Fryknäs M, Mansoori S, Linder S, Gullbo J, Larsson R, Nygren P. A novel spheroid model identifies selective enhancement of radiation by an inhibitor of oxidative phosphorylation. Oncotarget. 2019, 10: 5372-5382.
  10. Rubin J, Mansoori S, Blom K, Berglund M, Lenhammar L, Andersson C, Loskog A, Fryknäs M, Nygren P, Larsson R. Mebendazole stimulates CD14+ myeloid cells to enhance T-cell activatin and tumour cell killing. Oncotarget 2018, 9:30805.
Senast uppdaterad: 2023-01-30
Skriv ut